全文获取类型
收费全文 | 732篇 |
免费 | 1篇 |
国内免费 | 1篇 |
专业分类
化学工业 | 1篇 |
金属工艺 | 1篇 |
轻工业 | 10篇 |
一般工业技术 | 2篇 |
冶金工业 | 720篇 |
出版年
2017年 | 1篇 |
2010年 | 1篇 |
2008年 | 1篇 |
2004年 | 1篇 |
2003年 | 4篇 |
2000年 | 6篇 |
1999年 | 19篇 |
1998年 | 188篇 |
1997年 | 116篇 |
1996年 | 60篇 |
1995年 | 42篇 |
1994年 | 46篇 |
1993年 | 55篇 |
1992年 | 9篇 |
1991年 | 16篇 |
1990年 | 16篇 |
1989年 | 22篇 |
1988年 | 13篇 |
1987年 | 10篇 |
1986年 | 10篇 |
1985年 | 11篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 1篇 |
1980年 | 4篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 20篇 |
1976年 | 51篇 |
1955年 | 1篇 |
排序方式: 共有734条查询结果,搜索用时 15 毫秒
41.
WP Su 《Canadian Metallurgical Quarterly》1987,35(17):9245-9246
42.
We report a case of neurosarcoidosis, which simulated a cerebral tumor located at the floor of the III ventricle, associated to an aseptic meningitis and diabetes insipidus. It was the first and only manifestation of the illness. The response to steroid therapy was very favourable, with complete clinical recuperation and radiological resolution. 相似文献
43.
WP Anderson 《Canadian Metallurgical Quarterly》1997,167(11-12):608-609
44.
R Pazdur E Diaz-Canton WP Ballard JE Bradof S Graham SG Arbuck JL Abbruzzese R Winn 《Canadian Metallurgical Quarterly》1997,15(8):2905-2909
PURPOSE: The camptothecin derivative irinotecan has demonstrated clinical activity in metastatic colorectal carcinoma in both chemotherapy-naive and fluorouracil-refractory patients. 9-Aminocamptothecin (9-AC; NSC 603071), another camptothecin derivative, was selected for clinical development based on preclinical activity, including cures in human tumor xenografts resistant to standard anticancer agents. We report a phase II trial of 9-AC in patients with previously untreated metastatic colorectal carcinoma. PATIENTS AND METHODS: Colorectal cancer patients with measurable disease, a performance status of 0 to 2 (Zubrod), and no prior chemotherapy for metastatic disease received 9-AC. A cycle of therapy was 35 microg/m2/h for 72 consecutive hours (840 microg/m2/d for 3 days) and rest on days 4 to 14; a course of therapy was defined as two cycles (28 days). Patients were assessed for response after two courses. RESULTS: Seventeen patients with metastatic colorectal cancer were entered onto this trial. No complete or partial responses were noted. Treatment was well tolerated; toxic effects consisted mainly of neutropenia, nausea, vomiting, stomatitis, fatigue, and anemia. Grade 3 to 4 toxicity was limited to neutropenia (grade 3 in four patients and grade 4 in six), anemia (grade 3 in two patients), and vomiting (grade 3 in two patients). No grade 3 or 4 diarrhea occurred. Only two patients had their 9-AC dose reduced to 30 microg/m2/h. The median nadir absolute granulocyte count (AGC) was 1,500/microL. The median number of courses given was two and the median time to disease progression was 8 weeks. CONCLUSION: At the dose and schedule used in this trial, 9-AC lacked antitumor activity in metastatic colorectal cancer. 9-AC infusion schedules of longer duration are currently being investigated in this disease. 相似文献
45.
46.
47.
48.
49.
50.